Is IDYA or SLDB more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets IDEAYA Biosciences N/A -14.24% -13.09% Solid Biosciences N/A -73.42% -61.13%

Does the media refer more to IDYA or SLDB?

In the previous week, IDEAYA Biosciences had 5 more articles in the media than Solid Biosciences. MarketBeat recorded 9 mentions for IDEAYA Biosciences and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.28 beat IDEAYA Biosciences' score of 0.73 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, MBX or SLDB?

MBX Biosciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.21 N/A Solid Biosciences N/A N/A -$174.32M -$1.95 N/A

Is MBX or SLDB more profitable?

MBX Biosciences' return on equity of -24.52% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -24.52% -23.59% Solid Biosciences N/A -73.42% -61.13%

Does the media refer more to MBX or SLDB?

In the previous week, MBX Biosciences had 9 more articles in the media than Solid Biosciences. MarketBeat recorded 13 mentions for MBX Biosciences and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.28 beat MBX Biosciences' score of 0.85 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MOR or SLDB?

Solid Biosciences has a consensus price target of $17.11, suggesting a potential upside of 114.75%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Solid Biosciences 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91

Is MOR or SLDB more profitable?

Solid Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Solid Biosciences' return on equity of -73.42% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Solid Biosciences N/A -73.42% -61.13%

Which has higher earnings & valuation, IRON or SLDB?

Disc Medicine is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.58 N/A Solid Biosciences N/A N/A -$174.32M -$1.95 N/A

Is IRON or SLDB more profitable?

Disc Medicine's return on equity of -37.17% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -37.17% -33.65% Solid Biosciences N/A -73.42% -61.13%

Does the media refer more to IRON or SLDB?

In the previous week, Disc Medicine had 12 more articles in the media than Solid Biosciences. MarketBeat recorded 16 mentions for Disc Medicine and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.28 beat Disc Medicine's score of 0.57 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 5 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SLDB or RGC?

Solid Biosciences currently has a consensus price target of $17.11, suggesting a potential upside of 114.75%. Given Solid Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Solid Biosciences is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solid Biosciences 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, SLDB or RGC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.95 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is SLDB or RGC more profitable?

Regencell Bioscience's return on equity of 0.00% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% Regencell Bioscience N/A N/A N/A

Solid Biosciences (SLDB) Competitors

$7.98 -0.09 (-1.05%)

As of 03:13 PM Eastern

Compare

SLDB vs. IDYA, MBX, MOR, IRON, and RGC

Should you buy Solid Biosciences stock or one of its competitors? MarketBeat compares Solid Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Solid Biosciences include IDEAYA Biosciences (IDYA), MBX Biosciences (MBX), MorphoSys (MOR), Disc Medicine (IRON), and Regencell Bioscience (RGC).

How does Solid Biosciences compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

In the previous week, IDEAYA Biosciences had 5 more articles in the media than Solid Biosciences. MarketBeat recorded 9 mentions for IDEAYA Biosciences and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.28 beat IDEAYA Biosciences' score of 0.73 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEAYA Biosciences has higher revenue and earnings than Solid Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$225.27M	13.74	-$113.70M	-$1.60	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

IDEAYA Biosciences currently has a consensus price target of $50.25, indicating a potential upside of 42.69%. Solid Biosciences has a consensus price target of $17.11, indicating a potential upside of 114.75%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Solid Biosciences is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

IDEAYA Biosciences' return on equity of -14.24% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Solid Biosciences	N/A	-73.42%	-61.13%

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

IDEAYA Biosciences has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.41, meaning that its stock price is 141% more volatile than the broader market.

Summary

IDEAYA Biosciences beats Solid Biosciences on 9 of the 15 factors compared between the two stocks.

How does Solid Biosciences compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

MBX Biosciences' return on equity of -24.52% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Solid Biosciences	N/A	-73.42%	-61.13%

MBX Biosciences currently has a consensus price target of $71.13, indicating a potential upside of 9.68%. Solid Biosciences has a consensus price target of $17.11, indicating a potential upside of 114.75%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Solid Biosciences is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

MBX Biosciences has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.41, meaning that its share price is 141% more volatile than the broader market.

MBX Biosciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

In the previous week, MBX Biosciences had 9 more articles in the media than Solid Biosciences. MarketBeat recorded 13 mentions for MBX Biosciences and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.28 beat MBX Biosciences' score of 0.85 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Solid Biosciences shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Solid Biosciences beats MBX Biosciences on 7 of the 12 factors compared between the two stocks.

How does Solid Biosciences compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Solid Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Solid Biosciences' return on equity of -73.42% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Solid Biosciences	N/A	-73.42%	-61.13%

MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.41, suggesting that its share price is 141% more volatile than the broader market.

Solid Biosciences has a consensus price target of $17.11, suggesting a potential upside of 114.75%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Solid Biosciences has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

In the previous week, Solid Biosciences had 4 more articles in the media than MorphoSys. MarketBeat recorded 4 mentions for Solid Biosciences and 0 mentions for MorphoSys. Solid Biosciences' average media sentiment score of 1.28 beat MorphoSys' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Solid Biosciences	Positive

Summary

Solid Biosciences beats MorphoSys on 14 of the 16 factors compared between the two stocks.

How does Solid Biosciences compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Disc Medicine has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Solid Biosciences has a beta of 2.41, indicating that its stock price is 141% more volatile than the broader market.

Disc Medicine's return on equity of -37.17% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Solid Biosciences	N/A	-73.42%	-61.13%

Disc Medicine presently has a consensus target price of $104.44, indicating a potential upside of 37.26%. Solid Biosciences has a consensus target price of $17.11, indicating a potential upside of 114.75%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Solid Biosciences is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Disc Medicine is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Disc Medicine had 12 more articles in the media than Solid Biosciences. MarketBeat recorded 16 mentions for Disc Medicine and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.28 beat Disc Medicine's score of 0.57 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	5 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Solid Biosciences beats Disc Medicine on 8 of the 13 factors compared between the two stocks.

How does Solid Biosciences compare to Regencell Bioscience?

Solid Biosciences (NASDAQ:SLDB) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

In the previous week, Solid Biosciences had 4 more articles in the media than Regencell Bioscience. MarketBeat recorded 4 mentions for Solid Biosciences and 0 mentions for Regencell Bioscience. Solid Biosciences' average media sentiment score of 1.28 beat Regencell Bioscience's score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Solid Biosciences	Positive
Regencell Bioscience	Neutral

Solid Biosciences currently has a consensus price target of $17.11, suggesting a potential upside of 114.75%. Given Solid Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Solid Biosciences is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Solid Biosciences has a beta of 2.41, suggesting that its share price is 141% more volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market.

Regencell Bioscience's return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Regencell Bioscience	N/A	N/A	N/A

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Solid Biosciences beats Regencell Bioscience on 9 of the 12 factors compared between the two stocks.

Get Solid Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLDB vs. The Competition

Export

Metric	Solid Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$783.66M	$3.52B	$6.80B	$12.69B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-4.08	7.37	281.87	25.11
Price / Sales	N/A	1,199.70	571.28	79.56
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	3.49	16.88	11.05	6.20
Net Income	-$174.32M	-$12.56M	$3.49B	$347.60M
7 Day Performance	0.99%	-0.88%	0.38%	0.81%
1 Month Performance	-26.49%	-7.65%	-4.35%	-3.68%
1 Year Performance	16.66%	48.84%	62.81%	20.29%

Solid Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLDB Solid Biosciences	2.4877 of 5 stars	$7.98 -1.1%	$17.11 +114.6%	+18.0%	$785.14M	N/A	N/A	100	Positive News
IDYA IDEAYA Biosciences	3.7485 of 5 stars	$36.45 +2.4%	$50.25 +37.8%	+46.3%	$3.13B	$218.71M	N/A	80	News Coverage Upcoming Earnings
MBX MBX Biosciences	2.102 of 5 stars	$66.46 +3.9%	$71.13 +7.0%	N/A	$3.04B	N/A	N/A	N/A
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
IRON Disc Medicine	2.224 of 5 stars	$79.21 +7.5%	$104.44 +31.9%	+30.6%	$2.81B	N/A	N/A	30	Earnings Report Upcoming Earnings Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLDB) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solid Biosciences (SLDB) Competitors

SLDB vs. IDYA, MBX, MOR, IRON, and RGC

How does Solid Biosciences compare to IDEAYA Biosciences?

Summary

How does Solid Biosciences compare to MBX Biosciences?

Summary

How does Solid Biosciences compare to MorphoSys?

Summary

How does Solid Biosciences compare to Disc Medicine?

Summary

How does Solid Biosciences compare to Regencell Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solid Biosciences (SLDB) Competitors

SLDB vs. IDYA, MBX, MOR, IRON, and RGC

How does Solid Biosciences compare to IDEAYA Biosciences?

Does the media refer more to IDYA or SLDB?

Which has better earnings & valuation, IDYA or SLDB?

Do analysts prefer IDYA or SLDB?

Is IDYA or SLDB more profitable?

Do insiders & institutionals have more ownership in IDYA or SLDB?

Which has more volatility & risk, IDYA or SLDB?

Summary

How does Solid Biosciences compare to MBX Biosciences?

Is MBX or SLDB more profitable?

Do analysts prefer MBX or SLDB?

Which has more volatility and risk, MBX or SLDB?

Which has stronger valuation and earnings, MBX or SLDB?

Does the media refer more to MBX or SLDB?

Do insiders & institutionals hold more shares of MBX or SLDB?

Summary

How does Solid Biosciences compare to MorphoSys?

Do insiders and institutionals hold more shares of MOR or SLDB?

Is MOR or SLDB more profitable?

Which has more risk and volatility, MOR or SLDB?

Do analysts prefer MOR or SLDB?

Which has preferable earnings and valuation, MOR or SLDB?

Does the media favor MOR or SLDB?

Summary

How does Solid Biosciences compare to Disc Medicine?

Which has more risk and volatility, IRON or SLDB?

Is IRON or SLDB more profitable?

Do analysts recommend IRON or SLDB?

Which has higher earnings & valuation, IRON or SLDB?

Do insiders & institutionals have more ownership in IRON or SLDB?

Does the media refer more to IRON or SLDB?

Summary

How does Solid Biosciences compare to Regencell Bioscience?

Which has better earnings & valuation, SLDB or RGC?

Does the media prefer SLDB or RGC?

Do analysts recommend SLDB or RGC?

Which has more volatility & risk, SLDB or RGC?

Is SLDB or RGC more profitable?

Do insiders & institutionals believe in SLDB or RGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools